Two advances in the management of Parkinson disease.
Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. Deep brain stimulation is remarkably effective in refractory cases and may well usher in a new era in the treatment of chronic neurologic disease.
Montgomery
Erwin B
EB
Center for Functional and Restorative Neuroscience, Department of Neurology, The Cleveland Clinic Foundation, Ohio 44195, USA.
D000367:Age Factors; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D052160:Benzothiazoles; D002230:Carbidopa / Q000627:therapeutic use; D020820:Dyskinesias / Q000209:etiology; D004599:Electric Stimulation Therapy; D005544:Forecasting; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000628:therapy*; D000077487:Pramipexole; D012307:Risk Factors; D013238:Stereotaxic Techniques; D013844:Thiazoles / Q000627:therapeutic use
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D007211:Indoles; D013844:Thiazoles; C046649:ropinirole; D007980:Levodopa; D000077487:Pramipexole; D002230:Carbidopa